A MULTI-CENTER OPEN LABEL PHASE 1/2 STUDY OF CYT-0851 AN ORAL RAD51 INHIBITOR IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES AND ADVANCED SOLID TUMORS
Brief description of study
The purpose of the study to determine the safety of CYT-0851 in patients with relapsed/refractory B-Cell malignancies and advanced solid tumors. The study drug CYT-0851 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.
Clinical Study Identifier: s20-00047
ClinicalTrials.gov Identifier: NCT03997968
Principal Investigator:
Nina Beri.
Other Investigators:
Nila Theresa De La Rosa,
Elaine Shum,
Scot Niglio,
Vamsidhar Velcheti,
Janice Mehnert,
Maya Dimitrova,
Elise M Zahriah,
Salman Rafi Punekar,
Jonathan B Kahn,
Christy Lynn Spalink,
Joshua K Sabari,
Keriann M Scavone,
Cosmin Adrian Tegla,
Avital Benson,
Kathleen M Lutz,
Maryann J Kwa,
Christina Grace Wilson,
Jessica Wang,
Carol M Lee,
Sally Lau,
Elizabeth Kathleen Job,
Zujun Li,
Kristen Spencer,
Kathleen M Madden,
Ann M Riccobene,
Bhavana Pothuri,
Douglas K Marks.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
